Why the study?
Does the development of de novo donor-specific antibodies to DQ antigens increase the risk of death or graft dysfunction in heart transplant recipients compared to non-DQ antibodies or no antibodies?
Population
122 consecutive heart transplantation (HTx) recipients
Comparison
Development of de novo donor-specific antibodies… vs Development of non-DQ dnDSA or free from dnDSA
Design
Cohort
Follow-up
3.3 years
Authors
Loading...
dnDSA to DQ may worsen post-HTx outcomes; leaves open whether antigen-specific monitoring alters management.
Does the development of de novo donor-specific antibodies to DQ antigens increase the risk of death or graft dysfunction in heart transplant recipients compared to non-DQ antibodies or no antibodies?
De novo donor-specific antibodies to DQ antigens following heart transplantation are associated with a significantly increased risk of death and graft dysfunction compared to non-DQ antibodies.
Cole et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: